Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?

GR Connors, L Christopher-Stine, CV Oddis, SK Danoff - Chest, 2010 - journal.chestnet.org
The idiopathic inflammatory myopathies (IIMs) affect more than 60,000 individuals in the
United States and an estimated 770,000 worldwide. 1 Although widely considered a disease …

Idiopathic inflammatory myopathies and the lung

JC Lega, Q Reynaud, A Belot, N Fabien… - European …, 2015 - Eur Respiratory Soc
Idiopathic inflammatory myositis (IIM) is a group of rare connective tissue diseases (CTDs)
characterised by muscular and extramuscular signs, in which lung involvement is a …

[HTML][HTML] Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy …

Z Betteridge, S Tansley, G Shaddick, H Chinoy… - Journal of …, 2019 - Elsevier
Objectives To determine prevalence and co-existence of myositis specific autoantibodies
(MSAs) and myositis associated autoantibodies (MAAs) and associated clinical …

Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis

K Kurasawa, S Arai, Y Namiki, A Tanaka… - …, 2018 - academic.oup.com
Objective We aimed to determine the outcome of combination therapy with tofacitinib (TOF)
in a case series of refractory rapidly progressive interstitial lung disease (ILD) associated …

Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients

R Aggarwal, E Cassidy, N Fertig, DC Koontz… - Annals of the …, 2014 - ard.bmj.com
Objective To compare the cumulative survival and event free survival in patients with Jo-1
versus non-Jo-1 anti-tRNA synthetase autoantibodies (anti-synAb). Methods Anti-synAb …

Short‐term and long‐term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients

I Marie, PY Hatron, S Dominique, P Cherin… - Arthritis & …, 2011 - Wiley Online Library
Objective This study was undertaken to assess the characteristics and outcome of interstitial
lung disease (ILD) in polymyositis/dermatomyositis (PM/DM) and to determine variables …

The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody

R Nakashima, Y Imura, S Kobayashi, N Yukawa… - …, 2010 - academic.oup.com
Objectives. Various autoantibodies are detected in the sera of PM/DM patients. Some of
them are specific to PM/DM patients and closely associated with clinical manifestations of …

[HTML][HTML] Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease

H Hozumi, T Fujisawa, R Nakashima, T Johkoh… - Respiratory …, 2016 - Elsevier
Abstract Objectives Myositis-specific autoantibodies (MSAs) are associated with clinical
phenotypes in polymyositis/dermatomyositis (PM/DM). No study has investigated the clinical …

Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression

H Gunawardena, ZE Betteridge, NJ McHugh - Rheumatology, 2009 - academic.oup.com
The idiopathic inflammatory myopathies (IIMs)—DM and PM—have been historically defined
by broad clinical and pathological criteria. These conditions affect both adults and children …

Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive …

S Sato, M Kuwana, T Fujita, Y Suzuki - Modern rheumatology, 2013 - Taylor & Francis
Objectives: We examined the relationship between disease activity and anti-CADM-
140/MDA5 titer measured by enzyme-linked immunosorbent assay (ELISA). Methods: Sera …